Atrasentan: Hope for Long-Term IgA Nephropathy Treatment
- Atrasentan,marketed as Valrafia by Novartis,secured FDA approval earlier this year through an accelerated pathway.
- Richard Lafayette, a professor of medicine and nephrology at Stanford University Medical Center, is an investigator and steering committee member for the ALIGN study.
- The ALIGN trial, identified as NCT04573478, anticipates completion by Dec.
Atrasentan, marketed as Valrafia, has secured FDA approval for treating IgA nephropathy, and doesn’t require a REMS program. This streamlined process signals enhanced safety and tolerability. the absence of this program simplifies treatment for both physicians and patients.stanford nephrology expert Dr. Richard Lafayette discusses the implications, including the importance of avoiding pregnancy during atrasentan treatment and a necessary two-week washout period before conception. The ALIGN trial’s role in confirming clinical benefits is also examined.Wiht News Directory 3, stay updated.The medical community eagerly awaits the 2026 ALIGN trial results to confirm the drug’s long-term efficacy in slowing kidney function decline, presenting hope for individuals with IgA nephropathy. Discover what’s next in this groundbreaking treatment.
Atrasentan Doesn’t Need REMS for IgA Nephropathy: What It Means
Updated June 24,2025
Atrasentan,marketed as Valrafia by Novartis,secured FDA approval earlier this year through an accelerated pathway. The drug aims to reduce proteinuria in patients with primary immunoglobulin A (IgA) nephropathy. Approval hinged on initial findings from the phase 3 ALIGN study.
dr. Richard Lafayette, a professor of medicine and nephrology at Stanford University Medical Center, is an investigator and steering committee member for the ALIGN study. He addressed why atrasentan, an endothelin A receptor antagonist, does not require a REMS program. He also discussed potential adjustments for patients if the final ALIGN trial data fails to demonstrate a clinical benefit.
The ALIGN trial, identified as NCT04573478, anticipates completion by Dec. 18, 2026. The absence of a REMS program streamlines the treatment process for both physicians and patients, signaling confidence in the drug’s safety and tolerability.
Lafayette emphasized the importance of pregnancy avoidance with modern IgA nephropathy therapies, especially those involving endothelin receptor blockade. He clarified the protocol for patients considering pregnancy while on atrasentan.
The safety profile of this agent is such that there is no REMS needed, so first, that talks to safety and tolerability. And then, in practice, it’s realy critical, because it makes it a smoother transition.
Pregnancy is contraindicated during atrasentan treatment. Lafayette recommends a 2-week washout period after discontinuing the medication before attempting conception.
Regarding the possibility of the ALIGN trial failing to confirm clinical benefits, Lafayette acknowledged the rapid progress of new medications for iga nephropathy.He noted the availability of options like targeted budesonide, combinations of angiotensin receptor blockers and endothelin antagonists, and complement blockers.
despite these alternatives, Lafayette remains optimistic about atrasentan’s prospects. He cited the significant proteinuria reduction observed and the drug’s prior success in slowing the progression of diabetic kidney disease. He believes the FDA’s early approval decision reflects a comprehensive review of available data.
What’s next
The medical community awaits the final ALIGN trial results, expected in late 2026, to confirm the long-term benefits of atrasentan in slowing kidney function decline for individuals with IgA nephropathy. Continued monitoring and research will further refine treatment strategies for this condition.